CN117085035A - Composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and crafts and preparation method thereof - Google Patents
Composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and crafts and preparation method thereof Download PDFInfo
- Publication number
- CN117085035A CN117085035A CN202311279249.6A CN202311279249A CN117085035A CN 117085035 A CN117085035 A CN 117085035A CN 202311279249 A CN202311279249 A CN 202311279249A CN 117085035 A CN117085035 A CN 117085035A
- Authority
- CN
- China
- Prior art keywords
- molecular weight
- sodium hyaluronate
- skin
- weight sodium
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000037307 sensitive skin Effects 0.000 title abstract description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 62
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 60
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 60
- 206010042496 Sunburn Diseases 0.000 claims abstract description 8
- 210000003205 muscle Anatomy 0.000 claims abstract description 8
- 230000008439 repair process Effects 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 229920002125 Sokalan® Polymers 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 4
- 239000010931 gold Substances 0.000 claims description 4
- 229910052737 gold Inorganic materials 0.000 claims description 4
- 239000003906 humectant Substances 0.000 claims description 4
- 210000000744 eyelid Anatomy 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 229940040145 liniment Drugs 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 210000004207 dermis Anatomy 0.000 abstract description 3
- 230000003020 moisturizing effect Effects 0.000 abstract description 3
- 210000000434 stratum corneum Anatomy 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 206010052428 Wound Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 230000000172 allergic effect Effects 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- 206010042674 Swelling Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 3
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- 229920000426 Microplastic Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 229940043234 carbomer-940 Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/004—Aftersun preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and a preparation method thereof. The composition comprises: 0.4 to 2 parts of sodium hyaluronate and 0.005 to 0.2 part of polydeoxyribonucleotide; the sodium hyaluronate includes low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate, and high molecular weight sodium hyaluronate. The composition of the invention improves the stability of products by reasonably collocating low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate, high molecular weight sodium hyaluronate and polydeoxyribonucleotide, prolongs the acting time of active ingredients in skin, enables the active ingredients to enter dermis layers through stratum corneum and directly act on cell target sites, improves the bioavailability, has obvious effects of moisturizing, repairing, anti-inflammatory and the like, and can be effectively used for sunburn, sensitive muscle repairing and damaged skin repairing after medical arts.
Description
Technical Field
The invention belongs to the technical field of skin repair, and particularly relates to a composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and a preparation method thereof.
Background
The skin is the biggest immune barrier of the human body, prevents invasion of microorganisms and harmful substances, can maintain the stability of the internal environment of the human body, plays a key role in the health of the human body, and the wound can damage the integrity and the continuity of the skin of the human body.
Related researches show that the migration speed of wound epidermal cells is faster than that of an exposed wound surface environment in a moist healing environment, the sterile repair dressing can provide a moist environment for skin repair, regulate PH and grease balance, reconstruct skin microenvironment, provide auxiliary treatment and nursing for repair of small wounds or non-chronic wounds, and can also be used for repair of skin injury caused by skin microenvironment disorder.
Disclosure of Invention
The present invention aims to solve at least one of the technical problems in the prior art described above. Therefore, the invention provides a composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts.
The invention also provides a preparation method of the composition.
The invention also provides application of the composition.
The invention also provides a medicine.
According to one aspect of the present invention, a composition is presented, the composition comprising: 0.4 to 2 parts of sodium hyaluronate and 0.005 to 0.2 part of polydeoxyribonucleotide;
the sodium hyaluronate includes low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate and high molecular weight sodium hyaluronate;
the molecular weight of the low molecular weight sodium hyaluronate is 20kDa to 100kDa;
the molecular weight of the medium molecular weight sodium hyaluronate is 200kDa-800 kDa;
the molecular weight of the high molecular weight sodium hyaluronate is 800kDa to 1800kDa.
According to the invention, three kinds of sodium hyaluronate with different molecular weights (low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate and high molecular weight sodium hyaluronate) are reasonably matched and jointly encapsulated, so that the comprehensive effect is remarkable, wherein the low molecular weight sodium hyaluronate can enter the dermis layer through penetrating through the stratum corneum far and can be retained in high content; the medium molecular weight sodium hyaluronate enters the surface layer of the skin to maintain and retain moisture, and can cooperate with polydeoxyribonucleotide to balance melanocytes so as to avoid pigmentation; the high molecular weight sodium hyaluronate can form a breathable film on the surface of skin, so that the skin is locked with water, invasion of foreign bacteria, dust and ultraviolet rays is blocked, and the skin is protected from injury; sodium hyaluronate with different molecular weights and polydeoxyribonucleotide cooperate to improve bioavailability, and has remarkable effects of moisturizing, repairing, anti-inflammatory and the like.
In some embodiments of the present invention, the mass addition ratio of the low molecular weight sodium hyaluronate, the medium molecular weight sodium hyaluronate, and the high molecular weight sodium hyaluronate is (1 to 4): (1-3): (0.5-3).
In some embodiments of the invention, the composition further comprises the following components: 0.1 to 1 part of thickener and 0.5 to 2 parts of humectant.
In some embodiments of the invention, the thickener comprises at least one of carbomers or water soluble chitosan.
In some embodiments of the invention, the thickener comprises a carbomer; the carbomer is at least one selected from carbomer 940, carbomer 941 and carbomer 934.
In some embodiments of the invention, the humectant comprises at least one of glycerin, sorbitol, mannitol, xylitol, or glycols.
In some embodiments of the invention, the composition further comprises a preservative and a pH adjuster.
In some embodiments of the invention, the preservative comprises at least one of sodium methylparaben, benzoic acid, sodium benzoate, phenoxyethanol, sorbic acid, or sodium sorbate.
In some embodiments of the invention, the pH adjuster comprises triethanolamine.
In some embodiments of the invention, the composition further comprises water.
In a second aspect of the present invention, a method for preparing the above composition is provided, comprising the steps of: mixing the above components.
In a third aspect of the invention, there is provided the use of the above composition in the manufacture of a product for the treatment of sunburn.
In some embodiments of the invention, the use is in the manufacture of a product for the repair of sensitive muscles.
In some embodiments of the invention, the use is in the preparation of a product for repair of damaged skin after medical arts.
In some embodiments of the invention, the medical post-art damaged skin repair comprises at least one of spot removal, needle cleaning, double eyelid, and gold microneedle post-operative damaged skin repair.
In some embodiments of the invention, the products include pharmaceuticals, cosmetics, and medical devices.
In some embodiments of the invention, the product is a pharmaceutical.
In some embodiments of the invention, the medicament further comprises a pharmaceutical excipient.
In some embodiments of the invention, the pharmaceutical excipients include at least one of diluents, excipients, fillers, binders, disintegrants, absorption enhancers, surfactants, adsorption carriers, lubricants, sweeteners, and flavoring agents.
In some embodiments of the invention, the pharmaceutical dosage form is a gel, liniment, compress, paste or spray.
In a fourth aspect of the invention, an article of manufacture is provided comprising the composition described above for use in the treatment of sunburn, sensitive muscle repair and/or post-medical and artistic damaged skin repair.
In some embodiments of the invention, the articles include pharmaceuticals, cosmetics, and medical devices.
According to some embodiments of the invention, at least the following benefits are provided: the composition of the invention improves the stability of products by reasonably collocating low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate, high molecular weight sodium hyaluronate and polydeoxyribonucleotide, prolongs the acting time of active ingredients in skin, enables the active ingredients to enter dermis layers through stratum corneum and directly act on cell target sites, improves the bioavailability, has obvious effects of moisturizing, repairing, anti-inflammatory and the like, and can be effectively used for sunburn, sensitive muscle repairing and damaged skin repairing after medical arts.
Additional features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Drawings
The invention is further described with reference to the accompanying drawings and examples, in which:
FIG. 1 is a graph of the speckle reduction repair results in a test example of the present invention;
FIG. 2 is a graph of the results of needle cleaning repair in a test example of the present invention;
FIG. 3 is a graph showing the repair results of gold microneedles in a test example of the present invention.
Detailed Description
The conception and the technical effects produced by the present invention will be clearly and completely described in conjunction with the embodiments below to fully understand the objects, features and effects of the present invention. It is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments, and that other embodiments obtained by those skilled in the art without inventive effort are within the scope of the present invention based on the embodiments of the present invention.
In the embodiment of the invention, sodium hyaluronate and polydeoxyribonucleotide with different molecular weights are purchased from Guangzhou macro-control trade development limited company; polydeoxyribonucleotides were purchased from Hun Biotech Co.Ltd.
Example 1
The embodiment provides a composition which comprises the following components in percentage by weight: low molecular weight sodium hyaluronate with molecular weight of 20kDa-100kDa, medium molecular weight sodium hyaluronate with molecular weight of 200kDa-800kDa 0.2%, high molecular weight sodium hyaluronate with molecular weight of 800kDa-1800kDa 0.1%, carbomer 941.5%, polydeoxyribonucleotide 0.01%, glycerol 1%, sodium hydroxybenzoate 0.05%, triethanolamine 0.15%, and water in balance.
The preparation method of the composition of the embodiment comprises the following steps:
adding ultrapure water into the low molecular weight sodium hyaluronate with the molecular weight of 20kDa-100kDa, the medium molecular weight sodium hyaluronate with the molecular weight of 200kDa-800kDa, the medium molecular weight sodium hyaluronate with the molecular weight of 0.2%, the high molecular weight sodium hyaluronate with the molecular weight of 800kDa-1800kDa, carbomer 941.5%, polydeoxyribonucleotide 0.01%, glycerol 1%, sodium methylparaben 0.05% and triethanolamine 0.15%, uniformly mixing, and then sterilizing and packaging.
Example 2
The embodiment provides a composition which comprises the following components in percentage by weight: 0.1% of low molecular weight sodium hyaluronate with molecular weight of 20kDa-100kDa, 0.2% of medium molecular weight sodium hyaluronate with molecular weight of 200kDa-800kDa, 0.2% of high molecular weight sodium hyaluronate with molecular weight of 800kDa-1800kDa, 0.6% of carbomer 941, 0.02% of polydeoxyribonucleotide, 1% of glycerin, 0.05% of sodium hydroxybenzoate and 0.15% of triethanolamine.
The preparation method of the composition in this example was the same as in example 1.
Example 3
The embodiment provides a composition, which consists of the following components in percentage by weight: 0.3% of low molecular weight sodium hyaluronate with molecular weight of 20kDa-100kDa, 0.1% of medium molecular weight sodium hyaluronate with molecular weight of 200kDa-800kDa, 0.1% of high molecular weight sodium hyaluronate with molecular weight of 800kDa-1800kDa, 0.5% of carbomer 941, 0.02% of polydeoxyribonucleotide, 1% of glycerol, 0.05% of sodium hydroxybenzoate and 0.15% of triethanolamine.
The preparation method of the composition in this example was the same as in example 1.
Example 4
The embodiment provides a composition which comprises the following components in percentage by weight: 0.1% of low molecular weight sodium hyaluronate with molecular weight of 20kDa-100kDa, 0.3% of medium molecular weight sodium hyaluronate with molecular weight of 200kDa-800kDa, 0.1% of high molecular weight sodium hyaluronate with molecular weight of 800kDa-1800kDa, 0.5% of carbomer 941, 0.03% of polydeoxyribonucleotide, 1.5% of glycerol, 0.05% of sodium methylparaben, 0.15% of triethanolamine and the balance of water.
The preparation method of the composition in this example was the same as in example 1.
Comparative example 1
This example provides a composition that differs from example 1 only in that: does not contain sodium hyaluronate with low molecular weight.
The preparation method of the composition in this comparative example was the same as in example 1.
Comparative example 2
This comparative example provides a composition that differs from example 1 only in that: does not contain sodium hyaluronate with medium molecular weight.
The preparation method of the composition in this comparative example was the same as in example 1.
Comparative example 3
This comparative example provides a composition which differs from example 1 only in that: does not contain high molecular weight sodium hyaluronate.
The preparation method of the composition in this comparative example was the same as in example 1.
Comparative example 4
This comparative example provides a composition which differs from example 1 only in that: does not contain polydeoxyribonucleotides.
The preparation method of the composition in this comparative example was the same as in example 1.
Test examples
This test example tests the properties of the compositions prepared in examples 1-4 and comparative examples 1-4.
1. Security detection
The composition prepared in example 1 was subjected to safety test in accordance with cosmetic safety Specification (2015 edition) using an experimental rabbit. Selecting 4 healthy and adult rabbits, dividing the rabbits into 2 groups, and subtracting the fur from the two sides of the back spine of the animal before experiments, wherein the fur removal range is about 3cm multiplied by 3cm. The control was not treated. The experimental group adopts a self-comparison method of the left side and the right side of the same body, 0.5g of the test object is smeared on the dehaired skin on the right side of the back of the rabbit, the smearing area is 2.5cm multiplied by 2.5cm, and the application is carried out once a day for 14 days continuously; shearing hair before each application; the left depilatory area was not treated as a self-control. From the next day, the residual test sample was removed with warm water, and after 1 hour, the results were observed and scored according to the skin irritation response scoring criteria of cosmetic hygiene Specification (2015 edition). Through 14 days of observation experiments, the test animal has no systemic poisoning, and the local skin coated by the test object has no erythema, edema and other manifestations, so that the composition provided by the embodiment 1 of the invention has no irritation on multiple skin irritation.
2. In vitro sunburn repair experiments
Preparation of the mouse model:
54 SD rats were taken, the body weight was about 120g, and the male and female animals were randomly divided into 9 groups of 6 animals each. Rats were shaved on the back with an electric hair clipper prior to uv irradiation, with a consistent shaving area of 3 x 3cm. Grouping of test animals: blank group: after being damaged by ultraviolet irradiation, the fiber is not treated; experimental group: after damage by ultraviolet irradiation, the compositions of the present invention (the compositions prepared in examples 1 to 4 and comparative examples 1 to 4, respectively) were applied at a dose of about 0.5 g/time, once a day in the morning and evening. Skin crusting time and wound healing average time were recorded.
TABLE 1
| Group of | Animal number (only) | Scab time (d) | Wound healing time (d) |
| Example 1 | 6 | 0.32 | 7.12 |
| Example 2 | 6 | 0.45 | 7.93 |
| Example 3 | 6 | 0.39 | 7.64 |
| Example 4 | 6 | 0.41 | 7.73 |
| Comparative example 1 | 6 | 0.59 | 9.45 |
| Comparative example 2 | 6 | 0.52 | 9.13 |
| Comparative example 3 | 6 | 0.54 | 8.94 |
| Comparative example 4 | 6 | 0.49 | 8.76 |
| Negative control | 6 | 0.82 | 13.14 |
The results are shown in Table 1, from which it can be seen that the compositions of the examples of the present invention can be used for effective treatment of sunburn repair, and significantly reduce scab time and healing time compared to the negative control group.
3. Sensitive muscle repair experiments
Group of subjects: 70 skin allergy patients, aged 18-60 years, were informed consent.
Grouping: the study groups (treatment groups of the compositions prepared in examples 1-4 and comparative examples 1-4, respectively) were randomized into 9 groups of 8 subjects each, and the blank group was not treated with any treatment, and 6 subjects.
The treatment method comprises the following steps: the test groups were each applied with an equal amount of the corresponding composition (the compositions prepared in examples 1-4 and comparative examples 1-4, respectively) in the morning and evening, and the blank group was not subjected to any treatment and was subjected to a review for 5 days continuously.
Judgment standard: and (3) healing: the allergic phenomena such as skin redness, swelling, itching, skin loss and the like disappear; the method is effective: the allergic phenomena such as skin redness, swelling, itching, skin loss and the like are relieved; invalidation: the allergic phenomena such as skin redness, swelling, itching, skin loss and the like have no obvious change; weighting: the allergic phenomena such as skin redness and swelling, itching, skin damage and the like are worsened.
TABLE 3 Table 3
The results of the tests are shown in Table 2, and it can be seen from Table 2 that the compositions of the present invention can be effectively used for the treatment of sensitive muscles. The result shows that the composition prepared from the sodium hyaluronate with different molecular weights has obvious repair effect on allergic patients, and the composition has synergistic effect when added with polydeoxyribonucleotide.
4. Repair of damaged skin after medical arts
1. Double eyelid micro plastic operation repair
45 female volunteers with similar wound sizes, just completed the double eyelid-cutting micro plastic surgery, were randomly selected, and the ages of the female volunteers were 18-25 years.
45 female volunteers were randomly divided into 9 groups, each group corresponding to 5 persons, each group corresponding to the morning and evening of the compositions prepared in examples 1-4 and comparative examples 1-4, the positive control group was treated with commercially available scar repair ointment 1 time per day, about 1g each time, and the average time to complete repair and cure of the wound was recorded for each group of volunteers.
TABLE 3 Table 3
| Group of | The number of people | Average time to complete wound healing (d) |
| Example 1 | 5 | 43 |
| Example 2 | 5 | 51 |
| Example 3 | 5 | 47 |
| Example 4 | 5 | 49 |
| Comparative example 1 | 5 | 57 |
| Comparative example 2 | 5 | 53 |
| Comparative example 3 | 5 | 52 |
| Comparative example 4 | 5 | 50 |
| Positive control | 5 | 62 |
The results are shown in Table 3, from which it can be seen that the compositions prepared in accordance with the embodiments of the present invention are suitable for repair of medical surgical scars.
2. Clinical cases
(1) Plum women, 42 years old, performed spot-removing operation in beauty clinics, and applied the composition prepared in example 1 once a day in the morning and evening, and recovered completely for 15 days, as shown in fig. 1.
(2) Women, 24 years old, performed needle cleaning surgery in a beauty clinic, and applied the composition prepared in example 1 once a day, 10 days later, and recovered completely, as shown in fig. 2.
(3) Women, 28 years old, performed gold microneedle surgery in a cosmetic clinic, and applied the composition prepared in example 1 once a day in the morning and evening, and recovered completely for 15 days, as shown in fig. 3.
While the embodiments of the present invention have been described in detail, the present invention is not limited to the above embodiments, and various changes can be made without departing from the spirit of the present invention within the knowledge of those skilled in the art. Furthermore, embodiments of the invention and features of the embodiments may be combined with each other without conflict.
Claims (10)
1. A composition, wherein the composition comprises: 0.4 to 2 parts of sodium hyaluronate and 0.005 to 0.2 part of polydeoxyribonucleotide;
the sodium hyaluronate includes low molecular weight sodium hyaluronate, medium molecular weight sodium hyaluronate and high molecular weight sodium hyaluronate;
the molecular weight of the low molecular weight sodium hyaluronate is 20kDa to 100kDa;
the molecular weight of the medium molecular weight sodium hyaluronate is 200kDa-800 kDa;
the molecular weight of the high molecular weight sodium hyaluronate is 800kDa to 1800kDa.
2. The composition according to claim 1, wherein the mass addition ratio of the low molecular weight sodium hyaluronate, the medium molecular weight sodium hyaluronate and the high molecular weight sodium hyaluronate is (1 to 4): (1-3): (0.5-3).
3. The composition of claim 1, further comprising the following components: 0.1 to 1 part of thickener and 0.5 to 2 parts of humectant; preferably, the thickener comprises at least one of carbomer or water-soluble chitosan; preferably, the humectant comprises at least one of glycerin, sorbitol, mannitol, xylitol or glycols.
4. A process for the preparation of a composition as claimed in any one of claims 1 to 3, comprising the steps of: mixing the above materials.
5. Use of a composition according to any one of claims 1 to 3 for the preparation of a product for the treatment of sunburn.
6. Use of a composition according to any one of claims 1-3 for the preparation of a product for the repair of sensitive muscles.
7. Use of a composition according to any one of claims 1-3 for the preparation of a product for the repair of damaged skin after medical arts.
8. The use of claim 7, wherein the medical post-art damaged skin repair comprises at least one of spot removal, needle cleaning, double eyelid, and gold microneedle post-operative damaged skin repair.
9. The use according to any one of claims 5 to 7, wherein the products include pharmaceuticals, cosmetics and medical devices; preferably, the product is a medicament; more preferably, the medicament is in the form of a gel, liniment, dressing, ointment or spray.
10. An article comprising the composition of any one of claims 1-3 for use in the treatment of sunburn, sensitive muscle repair, and/or post-medical and artistic damaged skin repair.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311279249.6A CN117085035A (en) | 2023-09-28 | 2023-09-28 | Composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and crafts and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311279249.6A CN117085035A (en) | 2023-09-28 | 2023-09-28 | Composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and crafts and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117085035A true CN117085035A (en) | 2023-11-21 |
Family
ID=88782002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311279249.6A Pending CN117085035A (en) | 2023-09-28 | 2023-09-28 | Composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and crafts and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117085035A (en) |
-
2023
- 2023-09-28 CN CN202311279249.6A patent/CN117085035A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8008345B2 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
| Hickman et al. | Human Dermal Safety Studies with Eflornithine HCl 13.9% Cream (Vaniqa™), a Novel Treatment for Excessive Facial Hair | |
| AU2002317053A1 (en) | Dermal therapy using phosphate derivatives of electron transfer agents | |
| AU2012254214B2 (en) | A topical formulation for treatment of hyperkeratotic skin | |
| Fang et al. | The effectiveness of topical anti-scarring agents and a novel combined process on cutaneous scar management | |
| AU2012254214A1 (en) | A topical formulation for treatment of hyperkeratotic skin | |
| JP7395576B2 (en) | Compositions for the treatment of skin conditions | |
| US11696907B2 (en) | Wound healing composition | |
| CN105899221B (en) | Composition for skin based on algae and olive leaf extract | |
| WO2012049697A1 (en) | Preparation for antiwrinkle treatment based on caffeine micro - patches beta-glucan polysaccarides | |
| CN112022795A (en) | Skin care and repair composition, preparation method and application thereof | |
| CN117085035A (en) | Composition capable of effectively relieving/repairing sensitive skin, sunburned skin and damaged skin after medical arts and crafts and preparation method thereof | |
| CN105534830B (en) | A kind of maintenance method of bandage type body film and body skin | |
| CN106420399A (en) | Laser cosmetology nursing agent, preparation and use method thereof | |
| KR102012019B1 (en) | Patch for prevention and treatment of stretch mark | |
| CN110731933A (en) | allergy-relieving, moisturizing and anti-aging hand cream containing peony whole plant extract and preparation method thereof | |
| Tajarudin et al. | Prevention Of Incontinence-Associated Dermatitis Of Immobility Patients Using Aloe Verra Skin Barrier And Olive Oil | |
| US11865138B2 (en) | Methods and compositions for therapeutic skin treatments in dermatological procedures affecting skin's barrier | |
| CN111281940B (en) | Scar-removing composition and preparation method and application thereof | |
| US20160106797A1 (en) | Topical treatment of shingles | |
| RU2730852C2 (en) | Composition of ingredients for treating fungal skin diseases of feet and nails (versions) | |
| Smirnova et al. | Prospects for the use of a drug based on a complex of fatty acid esters in models of laboratory animals in vivo | |
| CN114469969A (en) | Application of pulsatilla saponin B5 in preparation of skin care products | |
| UA144637U (en) | COMPOSITION FOR LOCAL TREATMENT OF FUNGAL DISEASES OF SKIN AND NAILS | |
| DE102022202547A1 (en) | Topically applicable preparation to improve the condition of the skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |